ZA201903012B - Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) - Google Patents

Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Info

Publication number
ZA201903012B
ZA201903012B ZA2019/03012A ZA201903012A ZA201903012B ZA 201903012 B ZA201903012 B ZA 201903012B ZA 2019/03012 A ZA2019/03012 A ZA 2019/03012A ZA 201903012 A ZA201903012 A ZA 201903012A ZA 201903012 B ZA201903012 B ZA 201903012B
Authority
ZA
South Africa
Prior art keywords
nafld
steatohepatitis
nash
reversal
human
Prior art date
Application number
ZA2019/03012A
Other languages
English (en)
Inventor
Socorro Armendáriz Borunda Juan
Agustín Rogelio Magaña Castro José
HERNÁNDEZ ALDANA Nadiel
Original Assignee
Cell Therapy And Tech S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy And Tech S A De C V filed Critical Cell Therapy And Tech S A De C V
Publication of ZA201903012B publication Critical patent/ZA201903012B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2019/03012A 2016-11-11 2019-05-14 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) ZA201903012B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Publications (1)

Publication Number Publication Date
ZA201903012B true ZA201903012B (en) 2020-09-30

Family

ID=61193005

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/03012A ZA201903012B (en) 2016-11-11 2019-05-14 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (2) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
EP3716975A4 (en) * 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
EP4232063A4 (en) * 2020-10-23 2025-01-01 HAN, Hq BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Also Published As

Publication number Publication date
AR110057A1 (es) 2019-02-20
CL2019001280A1 (es) 2019-07-19
KR20190084056A (ko) 2019-07-15
IL266519A (en) 2019-07-31
AU2024200737A1 (en) 2024-02-22
JP2019535822A (ja) 2019-12-12
EP3539537A1 (en) 2019-09-18
AU2017358367A1 (en) 2019-05-30
MX364040B (es) 2019-04-11
PH12019501047A1 (en) 2019-12-11
RU2019116422A (ru) 2020-12-11
AU2017358367B2 (en) 2023-11-09
US20250325530A1 (en) 2025-10-23
JP2022173344A (ja) 2022-11-18
CA3043300A1 (en) 2018-05-17
CN110248646A (zh) 2019-09-17
US20230181550A1 (en) 2023-06-15
ECSP19031851A (es) 2019-06-30
MA45754A1 (fr) 2019-12-31
US20190262325A1 (en) 2019-08-29
PE20191149A1 (es) 2019-09-02
JOP20190102A1 (ar) 2019-05-06
RU2019116422A3 (enExample) 2021-04-09
CN115969802A (zh) 2023-04-18
WO2018088886A1 (es) 2018-05-17
CO2019004799A2 (es) 2019-07-31
KR20240065330A (ko) 2024-05-14
UY37478A (es) 2018-05-31
MX2016014775A (es) 2018-05-10

Similar Documents

Publication Publication Date Title
ZA201903012B (en) Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
IL281093B2 (en) Combinations for the treatment of NASH/NAFLD and related diseases
SG11202106144VA (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
ZA202103188B (en) Combination treatment of nafld and nash
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
ZA201807513B (en) Dispensing device and pharmaceutical composition for the treatment of rhinitis
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
IL282904A (en) Therapeutic microbiota for the treatment and/or prevention of dysbiosis
ZA202104378B (en) Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3716975A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
HUE063383T2 (hu) Folyékony készítmény az oro-faringo-laringo-özofageális traktus nyálkahártyájának kezelésében történõ felhasználásra
PT3595660T (pt) Compostos para utilização na prevenção e/ou tratamento de doença do fígado gordo não-alcoólico e esteato-hepatite nãoalcoólica
HK40092172A (zh) 含吡非尼酮缓释组合物用於治疗和逆转人脂肪性肝炎的药物用途
IL276228A (en) Compounds and preparations for the treatment of pain
IL282378A (en) A medicine for medical treatment and/or improvement of sepsis accompanied by the disease of the coagulation system
HK40057782A (en) Combination treatment of nafld and nash
PL3813843T3 (pl) Kompozycja do stosowania w zapobieganiu i/lub leczeniu chorób układu kostno-stawowego
GB201817346D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of diseases
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
HK40036525A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
HK40030474A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases